At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Study of Concurrent Cisplatin/Pemetrexed and RT Followed by Docetaxel in Stage III NSCLC (Non Small Cell Lung Cancer)
In Brief
A Phase 2 clinical trial evaluating Cisplatin, Docetaxel, and 2 other interventions for Lung Cancer. Completed, enrolled 29 participants across 2 sites.
Detailed Summary
RATIONALE: Drugs used in chemotherapy, such as cisplatin, pemetrexed disodium, and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving more than one chemotherapy drug (combination chemotherapy) together with radiation therapy may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving cisplatin and pemetrexed disodium together with radiation therapy followed by docetaxel works in treating patients with stage III non-small cell lung cancer.
Study Details
Timeline
Interventions
Cisplatin 75 mg/m2 every 3 weeks on days 1, 22, and 43
Docetaxel 75 mg/m2 on day 1 of each cycle
Pemetrexed 500 mg/m2 every 3 weeks on days 1, 22, and 43
Radiation therapy will begin within 24 hours of the first cycle of chemotherapy.